Last reviewed · How we verify
Octreotide Microspheres
Octreotide Microspheres is a Somatostatin analog Small molecule drug developed by Shanghai Zhongshan Hospital. It is currently in Phase 3 development for Neuroendocrine tumors (carcinoid syndrome, acromegaly, gastroenteropancreatic neuroendocrine tumors), Variceal bleeding in portal hypertension.
Octreotide microspheres are a long-acting formulation of the somatostatin analog octreotide that binds somatostatin receptors to inhibit hormone secretion and tumor growth.
Octreotide microspheres are a long-acting formulation of the somatostatin analog octreotide that binds somatostatin receptors to inhibit hormone secretion and tumor growth. Used for Neuroendocrine tumors (carcinoid syndrome, acromegaly, gastroenteropancreatic neuroendocrine tumors), Variceal bleeding in portal hypertension.
At a glance
| Generic name | Octreotide Microspheres |
|---|---|
| Sponsor | Shanghai Zhongshan Hospital |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Octreotide is a synthetic somatostatin analog that activates somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and hormone-secreting cells. The microsphere formulation provides sustained release over weeks to months, allowing for less frequent dosing while maintaining therapeutic levels. This mechanism suppresses excessive hormone secretion (such as growth hormone, insulin, and vasoactive peptides) and directly inhibits tumor cell proliferation in neuroendocrine malignancies.
Approved indications
- Neuroendocrine tumors (carcinoid syndrome, acromegaly, gastroenteropancreatic neuroendocrine tumors)
- Variceal bleeding in portal hypertension
Common side effects
- Abdominal pain/discomfort
- Diarrhea
- Nausea
- Injection site reactions
- Hyperglycemia
- Cholelithiasis
Key clinical trials
- Octreotide Microspheres for Preventing Pancreatic Fistula (PHASE3)
- A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET) (PHASE2)
- A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
- Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers (PHASE1)
- A Single-dose Study of Octreotide Injection in Healthy Adult Subjects (PHASE1)
- Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer (PHASE2)
- Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors (PHASE2)
- Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Octreotide Microspheres CI brief — competitive landscape report
- Octreotide Microspheres updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI
Frequently asked questions about Octreotide Microspheres
What is Octreotide Microspheres?
How does Octreotide Microspheres work?
What is Octreotide Microspheres used for?
Who makes Octreotide Microspheres?
What drug class is Octreotide Microspheres in?
What development phase is Octreotide Microspheres in?
What are the side effects of Octreotide Microspheres?
What does Octreotide Microspheres target?
Related
- Drug class: All Somatostatin analog drugs
- Target: All drugs targeting Somatostatin receptors (SSTR2, SSTR5)
- Manufacturer: Shanghai Zhongshan Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Neuroendocrine tumors (carcinoid syndrome, acromegaly, gastroenteropancreatic neuroendocrine tumors)
- Indication: Drugs for Variceal bleeding in portal hypertension
- Compare: Octreotide Microspheres vs similar drugs
- Pricing: Octreotide Microspheres cost, discount & access